CoChat

β-Amyloid25-35 inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism

Open access
Fernández-Tomé, Paz, Brera, Begoña, Arévalo, Marı́a-Angeles, de Ceballos, Marı́a L · 2004 · Neurobiology of Disease
Cited by 79

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Abstract Glutamate transporters are vulnerable to oxidants resulting in reduced uptake function. We have studied the effects of β-amyloid 25–35 (βA 25–35 ) on [ 3 H]-glutamate uptake on cortical neuron or astrocyte cultures in comparison with a scrambled peptide (SCR) and dihydrokainic acid (DHK), a prototypic uptake inhibitor. βA 25–35 was more potent than DHK in inhibiting glutamate uptake and the effects of both were more marked on astrocytes than on neurons. At 24 h, βA 25–35 dose-dependently (0.5–15 μM) increased glutamate levels in media from neuron cultures. DHK only enhanced extracellular glutamate at the highest concentration tested (2500 μM). βA 25–35 induced gradual neurotoxicity (0.1–50 μM) over time. Exposure to βA 25–35 resulted in increased uptake in astrocytes (0.25–5 μM) and neurons (0.5–15 μM) surviving its toxic effects. However, exposure to DHK (2.5–2500 μM) did not induce neurotoxicity nor modulated uptake. These results indicate that, while inhibition of glutamate uptake may be involved in the neurotoxic effects of βA 25–35 , enhancement of uptake may be a survival mechanism following exposure to βA 25–35 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2003.12.006

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 79

Metadata

Authors
Fernández-Tomé, P., Brera, B., Arévalo, M.-A., & de Ceballos, M. L.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2004-04
Volume
15
Issue
3
Pages
580-589
ISSN
0969-9961 (ISSN-L)
OpenAlex
W1985091026
Cited by
79
References
15
FWCI
0.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.